Bone Biologics expects to complete clinical trial enrollment by year-end

Go back to Bone Biologics expects to complete clinical trial enrollment by year-end

Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook

September 4, 2025 7:00 AM EDT

BURLINGTON, Mass.--(BUSINESS WIRE)-- Bone Biologics Corporation (Bone Biologics or the Company) (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that President and Chief Executive Officer Jeffrey Frelick has issued the following letter to stockholders.

To My Fellow Stockholders:

I am pleased to provide a progress report on Bone Biologics development of NB1 and to review our expected milestones for the coming year, including the anticipated completion of enrollment in our first-in-human study and an interim update. As a reminder, NB1 consists of the recombinant human protein NELL-1 (rhNELL-1) combined with demineralized... More